TY - JOUR
T1 - Glycosylated nanostructures in sublingual immunotherapy induce long-lasting tolerance in LTP allergy mouse model
AU - Rodriguez, Maria J.
AU - Ramos-Soriano, Javier
AU - Perkins, James R.
AU - Mascaraque, Ainhoa
AU - Torres, Maria J.
AU - Gomez, Francisca
AU - Diaz-Perales, Araceli
AU - Rojo, Javier
AU - Mayorga, Cristobalina
PY - 2019/12/1
Y1 - 2019/12/1
N2 - An effective specific immunotherapy should contain elements to generate specific recognition (T-cell peptides) and to modulate the immunological response towards a Th1/Treg pattern by enhancing dendritic cells (DCs). We propose a novel sublingual immunotherapy for peach allergy, using systems, that combine Prup3-T-cell peptides with mannose dendrons (D 1 ManPrup3 and D 4 ManPrup3). Peach anaphylactic mice were treated 1, 2 and 5 nM concentrations. Tolerance was assessed one/five weeks after finishing treatment by determining in vivo/in vitro parameters after challenge with Prup3. Only mice receiving D 1 ManPrup3 at 2 nM were protected from anaphylaxis (no temperature changes, decrease in Prup3-sIgE and -sIgG1 antibody levels, and secreting cells) compared to PBS-treated mice. Moreover, an increase of Treg-cells and regulatory cytokines (IL-10 + /IFN-γ + ) in CD4 + -T-cells and DCs were found. These changes were maintained at least five weeks after stopping treatment. D 1 ManPrup3 is an effective new approach of immunotherapy inducing protection from anaphylaxis which persists after finishing treatment.
AB - An effective specific immunotherapy should contain elements to generate specific recognition (T-cell peptides) and to modulate the immunological response towards a Th1/Treg pattern by enhancing dendritic cells (DCs). We propose a novel sublingual immunotherapy for peach allergy, using systems, that combine Prup3-T-cell peptides with mannose dendrons (D 1 ManPrup3 and D 4 ManPrup3). Peach anaphylactic mice were treated 1, 2 and 5 nM concentrations. Tolerance was assessed one/five weeks after finishing treatment by determining in vivo/in vitro parameters after challenge with Prup3. Only mice receiving D 1 ManPrup3 at 2 nM were protected from anaphylaxis (no temperature changes, decrease in Prup3-sIgE and -sIgG1 antibody levels, and secreting cells) compared to PBS-treated mice. Moreover, an increase of Treg-cells and regulatory cytokines (IL-10 + /IFN-γ + ) in CD4 + -T-cells and DCs were found. These changes were maintained at least five weeks after stopping treatment. D 1 ManPrup3 is an effective new approach of immunotherapy inducing protection from anaphylaxis which persists after finishing treatment.
UR - http://www.scopus.com/inward/record.url?scp=85062765815&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-40114-7
DO - 10.1038/s41598-019-40114-7
M3 - Article (Academic Journal)
C2 - 30858392
AN - SCOPUS:85062765815
SN - 2045-2322
VL - 9
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 4043
ER -